GeneDx Holdings Corp.
$ 77.08
10.76%
07 Aug - close price
- Market Cap 2,298,722,000 USD
- Current Price $ 77.08
- High / Low $ 78.23 / 69.61
- Stock P/E N/A
- Book Value 8.57
- EPS -3.63
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.08 %
- ROE -0.41 %
- 52 Week High 170.87
- 52 Week Low 32.21
About
Sema4 Holdings Corp. The company is headquartered in Stamford, Connecticut.
Analyst Target Price
$85.89
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-03 | 2026-05-04 | 2026-02-23 | 2025-10-28 | 2025-07-29 | 2025-04-30 | 2025-02-18 | 2024-10-29 | 2024-07-30 | 2024-04-29 | 2024-02-20 | 2023-10-30 |
| Reported EPS | 0.01 | -0.28 | 0.14 | 0.49 | 0.5 | 0.27 | 0.6353 | 0.04 | -0.1 | -0.33 | -0.69 | -0.82 |
| Estimated EPS | -0.19 | -0.0495 | 0.12 | 0.42 | 0.11 | 0.09 | 0.1033 | -0.21 | -0.3 | -0.67 | -0.75 | -1.31 |
| Surprise | 0.2 | -0.2305 | 0.02 | 0.07 | 0.39 | 0.18 | 0.532 | 0.25 | 0.2 | 0.34 | 0.06 | 0.49 |
| Surprise Percentage | 105.2632% | -465.6566% | 16.6667% | 16.6667% | 354.5455% | 200% | 515.0048% | 119.0476% | 66.6667% | 50.7463% | 8% | 37.4046% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: WGS
2026-08-07 23:11:37
Faruqi & Faruqi, LLP is investigating potential claims against GeneDx Holdings Corp. (NASDAQ: WGS) and reminds investors of the August 3, 2026 deadline to seek lead plaintiff status in a federal securities class action lawsuit. The lawsuit alleges that GeneDx and its executives made false and misleading statements regarding the importance of Fabric Genomics, the durability of reimbursement rates, and the company's gross margins. This follows a significant drop in share price after GeneDx disclosed missed Q1 financial results and cut 2026 guidance, revealing a goodwill impairment charge related to the Fabric Genomics acquisition.
2026-08-03 20:39:59
GeneDx Holdings Corp. (WGS) filed its quarterly earnings report (Form 10-Q) for the period ended June 30, 2026. The report details a new financing structure involving an amended loan agreement for an additional $50 million, increasing debt capacity to $150 million, and a conditional share issuance of approximately $5 million to Blackstone affiliates, which could dilute existing shareholders. The company reported a net loss of $17.7 million for Q2 2026 and $81.1 million for the six months ended June 30, 2026, and also recorded a $31.3 million impairment loss related to the Fabric Genomics acquisition.
2026-08-03 15:41:22
Faruqi & Faruqi, LLP reminds investors of the August 3, 2026, deadline to seek lead plaintiff status in a federal securities class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS). The lawsuit alleges that GeneDx and its executives made false and misleading statements regarding the importance of Fabric Genomics, its margins, and reimbursement rates, leading to significant stock price drops. Investors who purchased WGS stock between April 16, 2025, and May 4, 2026, and suffered losses are encouraged to contact the law firm.
2026-08-03 13:41:22
Schall, Brown & Schwartz LLP (SBS) is reminding investors of a class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS) for alleged securities fraud. The lawsuit claims GeneDx made misleading statements, revealed a drop in adjusted gross margin, lowered projected earnings, and announced a significant impairment, causing investor damages. Shareholders who purchased WGS shares during the class period (April 16, 2025, to May 4, 2026) are encouraged to contact SBS to discuss potential lead plaintiff appointments before the August 3, 2026 deadline.
2026-08-02 16:09:47
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS) on behalf of investors who purchased securities between April 16, 2025, and May 4, 2026. The lawsuit alleges that GeneDx made materially false and misleading statements regarding the importance of Fabric Genomics, its declining margins, and non-durable reimbursement rates. Investors who suffered losses are encouraged to contact the firm to explore their options, with a lead plaintiff deadline of August 3, 2026.
2026-08-01 22:09:47
The Rosen Law Firm is reminding investors who purchased common stock of GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025, and May 4, 2026, of the August 3, 2026, lead plaintiff deadline for a securities fraud lawsuit. The lawsuit alleges that GeneDx made misleading statements regarding the positive impact of its Fabric acquisition on the company's financials and operations, when in reality, significant problems existed that negatively impacted the business. Investors with losses exceeding $100,000 are encouraged to join the class action to seek compensation.
